Introduction
============

In some aging diseases, the accumulation of autofluorescent lipofuscin granules can signify an impaired clearance of waste material by lysosomes. Many degradative lysosomal enzymes are pH sensitive, with optimal activity in acidic environments. Lysosomal alkalinization has been detected in models of neural degenerative diseases of accumulation, such as early-onset Alzheimer's disease ([@B22], [@B21]; [@B9]) and Stargardt's retinal dystrophy ([@B25]).

Retinal pigmented epithelial (RPE) cells are particularly sensitive to perturbations in lysosomal enzyme activity, as they are responsible for phagocytosing the lipid-rich photoreceptor outer segment (POS) tips that are shed daily. The accumulation of autofluorescent lipofuscin waste may contribute to the early pathological changes leading age-related macular degeneration (AMD); dry geographic atrophy and wet neovascularization forms of AMD are now thought to stem from the intermediate AMD stage, where RPE cells are characterized by the accumulation of intracellular lipofuscin and extracellular drusen debris ([@B12]). The accumulation of lipofuscin in RPE cells is associated with increases in the retinoid by-product *N*-retinylidene-*N*-retinylethanolamine (A2E), and A2E levels are increased in RPE cells from the ABCA4^-/-^ mouse model of recessive Stargardt's retinopathy ([@B8]). Furthermore, A2E can lead to elevation of lysosomal pH, although the delay between drug application and alkalinization suggests an indirect pathway ([@B19]; [@B25]; [@B43]). This alkalinization may reduce lysosomal activity and contribute to a secondary accumulation of oxidized lipid waste.

Restoring an acidic environment to compromised lysosomes in RPE cells is predicted to enhance activity of pH-sensitive lysosomal enzymes and improve degradation, thus reducing the pathologies associated with accumulation of waste material ([@B17]). While several pathways capable of acidifying compromised lysosomes and improving degradative function have been identified in RPE cells, manipulation of cytoplasmic cAMP was particularly effective ([@B25]). Drugs targeting receptors coupled to stimulatory G protein (G~s~) reduced lysosomal pH and enhanced the clearance of lysosomal waste and opsin turnover in RPE cells fed POSs ([@B25]; [@B16]). Importantly, this approach was also effective at lowering lysosomal pH when given to RPE cells isolated from ABCA4^-/-^ mice ([@B24]; [@B17]). While these *in vitro* experiments provided proof of concept that drugs linked to cAMP could lower lysosomal pH and enhance lysosomal degradation, the *in vivo* translation of this approach required identification of the appropriate receptor target.

Several factors make the P2Y~12~ receptor antagonist ticagrelor (Brilinta) an attractive choice to target lysosomal accumulations in RPE cells. As the P2Y~12~ receptor for adenosine di-phosphate (ADP) is coupled to G~i~, antagonizing the P2Y~12~ raises cAMP ([@B7]). Several P2Y~12~ receptor antagonists are widely used as antithrombotic agents and are approved for use in elderly patients ([@B28]). Ticagrelor is a reversible allosteric P2Y~12~ receptor antagonist that does not require hepatic activation, removing complications associated with genetic variants of the enzyme CYP2C19 common with other P2Y~12~ antagonists used clinically ([@B5]; [@B42]). Ticagrelor is broadly utilized clinically to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome or a history of myocardial infarction ([@B39]; [@B6]). Finally, the P2Y~12~ receptor is expressed in cultured human ARPE-19 cells ([@B35]). In this initial study, we examined whether ticagrelor lowers lysosomal pH and reduce lysosomal autofluorescence in RPE cells from the ABCA4^-/-^ mouse model of retinal degeneration.

Materials and Methods {#s1}
=====================

Animal Care and Use
-------------------

All procedures were approved by the University of Pennsylvania IACUC in compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. C57BL/6J and ABCA4^-/-^ mice were reared at 5--15 lux and sacrificed using CO~2~. C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME, United States). ABCA4^-/-^ mice were obtained from Dr. Gabriel Travis of UCLA. All mice were negative for the RD8 mutation ([@B14]). Mouse eyes were isolated and RPE cells processed as described previously ([@B24]).

P2Y~12~ Receptor Pharmacological Agents
---------------------------------------

Ticagrelor was delivered in food or water at concentrations relevant to those used clinically in humans. The recommended maintenance dosage for ticagrelor (AZD6140) in humans of approximate mass of 90 kg is 180 mg per day; thus 2 mg/kg translated to 0.06 mg per diem for a 30 g mouse. Clinically dosed ticagrelor tablets (90 mg, Lot \# YK0083 from the University of Pennsylvania pharmacy) were powdered and initially dissolved in water at 12 μg/ml to give 0.06 mg per diem, based on a mean water consumption of 5 ml per diem. (The concentration was adjusted to 10 μg/ml for later experiments to match the stated solubility more precisely, although precipitate was not detected in either concentration.) The solution was administered in tinted light-resistant bottles wrapped with black paper and refreshed every 1--2 days for 5--19 days. No clear correlation was found between exposure time or concentration, and lysosomal pH signal. Ticagrelor was delivered in food using a custom mouse diet containing 0.1% ticagrelor in Purina Lab Meal 5001 was made by MP Biomedicals (Lot \#P9748, Santa Ana, CA, United States) from purified drug provided by AstraZeneca. Untreated food pellets or those containing 0.1% ticagrelor were added at 100--200 g every week and the remainder weighed to determine total food consumption. Ticagrelor has a pIC~50~ at the human P2Y~12~ receptor of 8.0 ([@B30]). The pIC~50~ of ticagrelor in an ADP-induced whole blood platelet aggregation assay in humans is 6.6, similar to that in mouse. Ticagrelor is reported to be quickly absorbed from the gut, reaching a peak concentration in 1.5 h, with blood plasma levels linearly dependent on the dose ([@B13]).

MeS-ADP; 2-(Methylthio)adenosine 5′-diphosphate (catalogue \#1624, Tocris Bio-Techne Corporation, Minneapolis, MN, United States), which has a pIC~50~ of 8.2 and 7.9 at the P2Y~1~ and P2Y~12~ receptors, respectively ([@B20]), was supplied pre-dissolved in water at 10 mM and diluted. AR-C66931; *N*^6^-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-β,γ-dichloromethylene-ATP (a.k.a cangrelor, catalogue \#5720 Tocris) with a pIC~50~ of 9.4 ([@B20]), was stored as a 10 mM stock solution in water. AR-C66096; 2-propylthio-betagamma-difluoromethylene ATP tetrasodium salt (catalogue \#3321, Tocris) inhibits ADP-induced aggregation of washed human platelets pIC~50~ = 8.16 and was supplied pre-dissolved at a concentration of 10 mM.

Measurement of Lysosomal pH From RPE Cells
------------------------------------------

Lysosomal pH was measured as described using the dye LysoSensor Yellow/Blue DND-160 ([@B24]). In brief, RPE cells from pairs of treated and untreated mice were isolated, loaded with LysoSensor Yellow/Blue 160 DSN, washed, and loaded into wells of a plate reader; the autofluorescence in these cells was previously found to be negligible in cells loaded with LysoSensor 160 DSN ([@B25]). The limited number of cells precluded calibration to absolute pH, so data were analyzed as the ratio of light excited at 340 vs. 380 nm, an index of lysosomal pH ([@B17]). Lysosomal pH measurements were made with UV-Star 384-well plates (Grenier Bio One) to minimize the disruption of the signal at 340 nm. As these ratios can vary from experiment to experiment, values were normalized to enable results from multiple trials to be combined. Lysosomal pH was determined from cultured ARPE-19 cells as described ([@B15]).

Polymerase Chain Reaction (PCR)
-------------------------------

Total RNA was isolated from fresh mouse RPE/choroid cells using Trizol and the RNeasy mini kit (Qiagen, Inc.). RNA yield was determined by nanodrop 2000 spectrophotometer; 100 ng of total RNA was converted into cDNA using High Capacity RNA-to-cDNA kit (\#4387406, Applied Biosystems). Primer pairs for mouse P2Y~12~: Forward: CATTGCTGTACACCGTCCTG; Reverse: AACTTGGCACACCAAGGTTC; 212-bp product. PCR was performed with 2 μl first-strand DNA synthesis product, 50 mM MgCl~2~, and10 μM of each primer with the 0.5 μl first recombinant DNA polymerase (Platinum^®^ *Taq* DNA Polymerase; Applied Biosystems) at 95°C for 10 min, followed by 35 cycles at 95°C for 30 s, 60°C for 45 s, and 72°C for 1 min, with a final extension step at 72°C for 10 min. First-strand DNA synthesis was omitted from the negative control. Quantitative PCR (qPCR) was performed on isolated RPE/choroid from 16 month old C57BL6J or ABCA4^-/-^ mice. Total RNA (100 ng) was reverse transcribed and qPCR was performed using SYBR Green and the 7300 RealTimePCR system (Applied Biosystems, Corp.) as described ([@B26]) using the following primers: A1AR- F: ATCCCTCTCCGGTACAAGACAGT, R: ACTCAGGTTGTTCCAGCCAAAC ([@B41]); A3AR- F: ACTTCTATGCCTGCCTTTTCATGT, R: AACCGTTCTATATCTGACTGTCAGCTT ([@B41]); CFH- F:ACCACATGTGCCAAATGCTA; R:TGTTGAGTCTCGGCACTTTG ([@B34]); ENT1- F:CTTGGGATTCAGGGTCAGAA, R: ATCAGGTCACACGACACCAA ([@B11]); P2Y12- F: CATTGCTGTACACCGTCCTG, R: AACTTGGCACACCAAGGTTC ([@B44]). Data were analyzed using the delta-delta CT approach, with results expressed as fold change in gene expression.

Microscopy and Immunocytochemistry
----------------------------------

Freshly isolated RPE cells from C57Bl6J mice were cultured for 1 day and fixed in 4% paraformaldehyde (PFA), rinsed with Duebcco's phosphate buffered saline (DPBS), permeabilized at room temperature in 0.1% Triton X-100 for 10 min, then blocked with 10% goat serum in SuperBlock blocking buffer (\#37515, Thermo Fisher Scientific) for 60 min. Anti- mouse P2Y~12~ antibody (1:50 dilution, \#AS-55043A, AnaSpec, Inc., Fremont, CA, United States) was added overnight at 4°C, followed by incubation in donkey anti-rabbit Alexa-Fluor 568 (1:500 dilution; Invitrogen, Carlsbad, CA, United States). Slides were mounted in Slow Fade Gold Antifade Mountant (Thermo Fisher Scientific) and imaged using a Nikon Eclipse 600 microscope (Nikon USA, Melville, NY, United States). To quantify the autofluorescence found in RPE whole mounts from ABCA4^-/-^ mice, images were obtained at 488 nm ex/\>540 nm em from 16 regions using a Nikon Eclipse 600 microscope and autofluorescence was measured using the Nikon Elements software. Spectral analysis of RPE cells in ABCA4^-/-^ mice was performed on 7 μm thick sections from the central 1/3^rd^ of the retina following standard fixation ([@B1]) using the Nikon A1R Laser Scanning Confocal Microscope and Nikon NIS-Elements software package at the University of Pennsylvania Live Cell Imaging Core. The endogenous autofluorescent spectral profile of ABCA4^-/-^ mouse RPE was collected after excitation by 406, 488, 561, and 639 lasers. The RPE layer was visualized with a 60X objective and emission was determined in 2.5 nm wide bins throughout the spectrum, grouped into 32 bins per sweep. Confocal scan settings were maintained from sample to sample, and pairs of treated and untreated sections were processed in parallel when possible to minimize day-to-day variations. ROI's were drawn along the RPE layer and corresponding emission levels were exported for analysis.

ARPE-19 Cell Culture
--------------------

ARPE-19 cells (American Tissue Type Collection, Manassas, VA, United States) were grown as described previously ([@B35]). In brief, cells were grown in 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium with 3 mM [L]{.smallcaps}-glutamine, 100 g/ml streptomycin and 10% FBS (all Thermo Fisher Scientific, Inc., Waltham, MA, United States). Cells were incubated at 37°C in 5% CO~2~ and subcultured weekly with 0.05% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA).

*In Vitro* Autofluorescence Model
---------------------------------

ARPE-19 cells were grown to confluence in 6-well plates, then treated with the pulse chase chloroquine/POS protocol as described ([@B16]). Cells were incubated with 2 ml POS for 2 h; POS were isolated as previously described ([@B24]). Cells were washed thoroughly with medium to remove non-internalized POS followed by a 2 h chase in DMEM/F12. Subsequently, the medium was removed and the cells incubated for 20 h with one of the following solutions: DMEM/F12, 10 μM CHQ, CHQ + 10 μM AR-C66096. This protocol was repeated daily. After 6 days the cells were repeatedly washed, detached with trypsin, and analyzed on a flow cytometer (FACS Calibur; BD Biosciences, Heidelberg, Germany) at the Penn PDM Flow Cytometry Facility. The FITC channel (excitation laser wavelength, 488 nm; detection filter wavelength, 530 nm) was used with a gate set to exclude cell debris and cell clusters.

Magic Red Staining
------------------

Magic Red powder was reconstituted as per the manufacturer's instructions (Bio-Rad, Inc., Hercules, CA, United States). ARPE-19 cells grown on coverslips were exposed to 10 μM tamoxifen or control solution. Magic Red was diluted into PBS 1:26 and applied to the cells for 30 min, followed by a 5 min incubation of 50 nM LysoTracker Green. Magic Red was visualized at 540 nm ex and LysoTracker Green at 488 nm using the Nikon Eclipse 600, as above.

Data Analysis
-------------

All data are given as mean ± standard error of the mean. Analysis was performed using SigmaStat (Systat Software, Inc., San Jose, CA, United States) and/or GraphPad Software, Inc. (La Jolla, CA, United States). Differences between treatments were analyzed using a one-way analysis of variance (ANOVA) with indicated *post hoc* tests as appropriate, or a Student's *t*-test using unpaired or paired configuration where appropriate.

Results
=======

Systemic Delivery of P2Y~12~ Antagonist Ticagrelor Lowers Lysosomal pH in RPE Cells From ABCA4^-/-^ Mice
--------------------------------------------------------------------------------------------------------

Initial experiments to determine whether ticagrelor decreased lysosomal pH in RPE cells from ABCA4^-/-^ mice were carried out by adding ticagrelor to the drinking water. Mice were given free access to drinking water only or water containing 10--12 μg/ml ticagrelor for 4--19 days. Fresh solution was provided every 1--2 days. Measurements of remaining water suggested ticagrelor did not alter consumption. Age- and gender-matched ABCA4^-/-^ mice used for this experiment examined daily appeared healthy and exhibited normal behavior with no increased bleeding events noted. Previous work suggest lysosomal pH must be measured from freshly isolated RPE cells from ABCA4^-/-^ mice, as the effect of lipofuscin on the lysosomal pH is altered by each cell division ([@B17]). As such, lysosomal pH levels could only be determined accurately from only pair of one untreated and one treated mouse per day.

Ticagrelor acidified the lysosomes of RPE cells from ABCA4^-/-^ mice. The lysosomal pH signal was reduced in RPE cells from treated mice as compared to untreated mice in all pairs examined, leading to a significant decline when averaged together (**Figure [1A](#F1){ref-type="fig"}**). The presence of the P2Y~12~ receptor in mouse RPE cells was confirmed at the mRNA level (**Figure [1B](#F1){ref-type="fig"}**) and using immunocytochemistry; expression was concentrated near the cell membrane consistent with a membrane-associated receptor (**Figure [1C](#F1){ref-type="fig"}**). Quantitative PCR indicated no difference in the expression of P2Y~12~ mRNA in RPE cells from C57BL/6J and ABCA4^-/-^ mice (**Figure [1D](#F1){ref-type="fig"}**).

![Ticagrelor lowers lysosomal pH in ABCA4^-/-^ mice. **(A)** Decline in the ratio of LysoSensor YellowBlue DNS 160 fluorescence excited at 340 vs. 380 nm in freshly isolated RPE cells from 20-month old untreated ABCA4^-/-^ mice (black circles) and those treated with 10--12 μg/ml ticagrelor in water (red squares). As mice were processed in pairs in individual days, lines connect mean measurements from treated and untreated pairs processed in parallel. ^∗^*p* = 0.029, *n* = 5, each circle represents the mean of 5--6 wells. **(B)** RT-PCR (+) shows P2Y~12~ receptor expression in RPE cells freshly isolated from mouse eyes (Fresh) or after 3 days in cell culture (Cultured). Bands are at the expected size of 212 bp. No product was detected when reverse transcriptase was omitted from the reaction (--). M-markers at 100 bp (see Supplementary Figure [3](#SM3){ref-type="supplementary-material"} for full gel). **(C)** Immunohistochemistry indicating expression of P2Y~12~ near the cell membrane of freshly isolated RPE cells from 9-month-old C57BL/6J mice. **(D)** Results from quantitative PCR assessment indicating there is no significant (NS) difference between expression of P2Y~12~ receptor mRNA from RPE/choroid of C57BL/6J (*n* = 4) and ABCA4^-/-^ mice (*n* = 3). **(E)** Ticagrelor added to a custom diet (0.1%) for 4 days was sufficient to lower lysosomal pH in RPE cells from ABCA4^-/-^ mice 7--8 months old (adult) (^∗^*p* = 0.0054, *n* = 14--17 measurements from three mice each condition). **(F)** Exposure to ticagrelor in food for 4 days did not reduce the mean signal in RPE cells from ABCA4^-/-^ mice aged 18--24 months (Old) (*p* = 0.514, *n* = 14--15 measures from three mice each condition). **(G)** Extending ticagrelor treatment to 28 days was sufficient to reduce lysosomal pH in the older mice (^∗^*p* = 0.0066, *n* = 15 measures from three mice each condition). Throughout, data are expressed as scatter plot with mean ± SEM of the ratio of light excited at 340/380 nm; values were normalized to the mean control for each day to account for differences in LysoSensor dye loading.](fphar-09-00242-g001){#F1}

In a separate study, ticagrelor was added to the mouse chow to confirm the ability of oral delivery to lower lysosomal pH in the RPE cells of ABCA4^-/-^ mice. Four days of exposure lowered the lysosomal pH in 7--8 month-old adult ABCA4^-/-^ mice, as compared to untreated mice (**Figure [1E](#F1){ref-type="fig"}**). Four days of treatment did not alter the lysosomal pH of RPE cells from 18 to 24 month-old mice compared to untreated controls (**Figure [1F](#F1){ref-type="fig"}**), but extending treatment to 28 days significantly reduced lysosomal pH in these older mice (**Figure [1G](#F1){ref-type="fig"}**). Plasma levels of ticagrelor in the mice treated with ticagrelor in food were 0.89 ± 0.07 μM (*n* = 13) and were undetectable in untreated mice.

P2Y~12~ Receptor Regulates Lysosomal pH *in Vitro*
--------------------------------------------------

The ability of ticagrelor to lower lysosomal pH was tested directly *in vitro* in the ARPE-19 cultured human cell line. The P2Y~12~ agonist Mes-ADP raised lysosomal pH in these cells (**Figure [2A](#F2){ref-type="fig"}**). Addition of ticagrelor (**Figure [2B](#F2){ref-type="fig"}**) or P2Y~12~ receptor antagonist AR-C66931 (**Figure [2C](#F2){ref-type="fig"}**) to the ARPE-19 cells reduced the lysosomal pH relative to MeS-ADP alone.

![Manipulation of the P2Y~12~ receptor alters lysosomal pH in ARPE-19 cells. **(A)** The lysosomal pH of ARPE-19 cells was elevated by P2Y~12~ receptor agonist methylthio ADP (MeS-ADP, 10 μM). ^∗^*p* = 0.002, *n* = 9--10. **(B)** Ticagrelor (20 μM) lowered the lysosomal pH in cells treated with MeS-ADP (^∗^*p* = 0.006, *n* = 13). **(C)** The P2Y~12~ receptor antagonist AR-C66931 (ARC, 10 μM) also reduced lysosomal pH in ARPE-19 cells treated with MeS-ADP (^∗^*p* = 0.033, *n* = 10). Data are expressed as the ratio of fluorescence excited at 340 vs. 380 nm in cells loaded with LysoSensor Yellow/Blue DNS 160; this is indicative of lysosomal pH, although absolute ratios varied with preparation; n represents the number of wells in a single trial with figures representative of 2--4 trials.](fphar-09-00242-g002){#F2}

P2Y~12~ Receptor Antagonists Reduce Autofluorescence
----------------------------------------------------

Lowering lysosomal pH increased clearance of autofluorescent material in prior *in vitro* work ([@B25], [@B24]; [@B4]; [@B16]). To determine whether ticagrelor could decrease autofluorescence *in vivo*, levels were determined from 16 regions of the RPE whole mount from untreated mice and those receiving ticagrelor in food (**Figure [3A](#F3){ref-type="fig"}**). There was considerable variation in the autofluorescence values in untreated mice. However, comparing the pattern of autofluorescence across all regions suggested there was a greater difference in autofluorescent levels in samples from the inferior/nasal region (**Figure [3B](#F3){ref-type="fig"}**). Representative images show the autofluorescence in untreated (**Figure [3C](#F3){ref-type="fig"}**) and treated mice (**Figure [3D](#F3){ref-type="fig"}**). Quantification indicated that the autofluorescence from RPE cells in the interior/nasal regions was reduced (**Figure [3E](#F3){ref-type="fig"}**) in mice treated with ticagrelor. However, there was no difference in mean levels in the superior/temporal regions (**Figure [3F](#F3){ref-type="fig"}**).

![Ticagrelor reduces autofluorescence in RPE cells from ABCA4^-/-^ mice. **(A)** A RPE whole mount preparation indicating the location of images obtained for autofluorescence quantification. **(B)** Heat map illustrating variation in intensity of autofluorescence (488 nm ex/\>525 nm em) in regions corresponding to those in "A." Each band is the mean of six untreated mice or mice treated with 0.1% ticagrelor in food for 28 days. Scale at right shows relative intensity. Images of autofluorescence excited at 488 nm in inferior regions of RPE wholemounts from untreated **(C)** and treated **(D)** ABCA4^-/-^ mice. **(E)** Autofluorescence intensity from regions 9--16 of six mice in each condition (*p* = 0.039, *n* = 48 measurements; eight from each mouse). **(F)** Autofluorescence intensity from regions 1--8 of six mice in each condition, *n* = 48). Mice were 257--333 days old after ticagrelor treatment. **(G)** Images from sections of the outer retina showing the RPE and photoreceptor outer segments (POSs) in untreated 20 month old ABCA4^-/-^ mice at 406 nm ex/\>409 nm em. The demarcation of two regions of interest (ROI) in the RPE layer are shown. Analogous image for 20 month old ABCA4^-/-^ mouse treated with 10 μg/ml ticagrelor in drinking water for 4 days. **(H)** Mean autofluorescence output for key excitation/emission pairs wavelengths (λ, as indicated; ^∗^*p* \< 0.05, *n* = 16 untreated, 10 treated sections from 4 to 5 mice respectively).](fphar-09-00242-g003){#F3}

To further characterize the effect of ticagrelor, autofluorescence in RPE cells was analyzed in retinal sections from untreated ABCA4^-/-^ mice and mice treated with ticagrelor. Increased autofluorescence in the RPE cells was detected in many sections from the untreated mice, as compared to those treated with ticagrelor (**Figure [3G](#F3){ref-type="fig"}**). While variation in autofluorescence levels across regions and mice was considerable, quantification of the autofluorescent output for a broad range of excitation/emission pairs showed a reduction, with emission at 571, 612, and 663 nm particularly effected (**Figure [3H](#F3){ref-type="fig"}**).

P2Y~12~ Receptor Antagonism Reduces Autofluorescence *in Vitro*
---------------------------------------------------------------

The effect of P2Y~12~ antagonism on autofluorescence was determined *in vitro* using FACS analysis following application of the pulse chase protocol for loading ARPE-19 cells with POSs and alkalinizing lysosomes with chloroquine (see section "Materials and Methods"). Cellular autofluorescence was increased by chloroquine alone, but the addition of POSs increased this autofluorescence substantially (**Figure [4A](#F4){ref-type="fig"}**). The P2Y~12~ receptor antagonist AR-C66096 reduced the autofluorescence produced by POSs in cells treated with chloroquine (**Figure [4B](#F4){ref-type="fig"}**). This suggests that blocking the P2Y~12~ receptor reduces lipofuscin accumulation in RPE cells *in vitro*, as it does *in vivo*.

![Blocking P2Y~12~ reduces RPE autofluorescence *in vitro.* **(A)** Treatment of ARPE-19 cells with POSs and 10 μM chloroquine (CHQ) using the pulse chase method led to a substantial rise in autofluorescence at 488 nm ex/\>525 nm em. FACS analysis demonstrates the increased autofluorescence with the CHQ/POS treatment for \>6 days. Treatment of cells with 10 μM P2Y~12~ receptor antagonist AR-C66096 shifted the autofluorescence curve to the left. **(B)** Quantification of the mean autofluorescence from five independent FACS trials showing a significant reduction in POS/CHQ autofluorescence excited at 488 nm in cells treated with 10 μM AR-C66096 (\#*p* = 0.02, \#\#*p* \< 0.001, ^∗^*p* = 0.014, *n* = 5). **(C)** ARPE-19 cells displaying overlap of Magic Red and LysoTracker Green, suggesting cathepsin B activity in lysosomes under control conditions (top). Magic Red staining was eliminated by elevation of lysosomal pH with 10 μM tamoxifen (bottom). **(D)** Tamoxifen (10 μM) raises lysosomal pH in ARPE-19 cells (^∗^*p* = 0.012, *n* = 13).](fphar-09-00242-g004){#F4}

To strengthen the link between lysosomal pH and degradative enzyme activity, ARPE-19 cells were stained with Magic Red to determine cathepsin B activity. The Magic Red substrate releases fluorescent cresyl violet in organelles containing cathepsin B that is catalytically active ([@B10]). Magic Red staining was substantial under control conditions; staining colocalized LysoTracker Green, consistent with the lysosomal localization of cathepsin B activity (**Figure [4C](#F4){ref-type="fig"}**). To determine whether rapid changes in lysosomal pH alter the activity of cathepsin B, cells were treated with tamoxifen, which raises lysosomal pH more rapidly and reproducibly than chloroquine in these cells (**Figure [4D](#F4){ref-type="fig"}**, [@B25]). Magic Red staining was absent in cells treated with tamoxifen, consistent with the pH dependence of degradative enzymes in ARPE-19 cells.

Ticagrelor and Gene Expression
------------------------------

The effect of ticagrelor on expression of several key genes in RPE cells was examined. Relative gene expression analysis using quantitative PCR showed a significant downregulation in the expression of the equilibrative nucleoside transporter 1 (ENT1), and complement factor H (CFH) in the RPE of mice treated with 0.1% ticagrelor in food for 14 days. There was no change in expression of mRNA for the P2Y~12~ receptor, the A~1~ adenosine receptor or the A~3~ adenosine receptor (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}).

Discussion
==========

We found that systemic delivery of ticagrelor lowered lysosomal pH in RPE cells of ABCA4^-/-^ mice. Lysosomal pH was reduced both by ticagrelor added to the drinking water, and by addition of ticagrelor to the mouse chow. Results from ticagrelor in food suggest older mice require longer treatment for lysosomal acidification. Ticagrelor, as well as the P2Y~12~ antagonist AR-C66931, lowered lysosomal pH in cultured human ARPE-19 cells, showing receptor block had a direct effect on lysosomal pH in RPE cells. Ticagrelor delivered orally also reduced autofluorescence in the inferior/nasal regions of these RPE cells, while block of the P2Y~12~ receptor reduced autofluorescence *in vitro* in ARPE-19 cells fed POSs. This provides the first evidence that systemic delivery of a P2Y~12~ antagonist improves lysosomal dysregulation in RPE cells.

Contribution of the P2Y12 Receptor
----------------------------------

Several observations implicate block of the P2Y~12~ receptor in the lysosomal acidification by ticagrelor. Previous studies indicated that elevation of cAMP, either directly or through drugs known to target the G~s~ protein that stimulates adenylate cyclase, lowered lysosomal pH in RPE cells from ABCA4^-/-^ mice when applied *ex vivo*, and in compromised ARPE-19 cells ([@B25], [@B24]; [@B16], [@B18]). This lysosomal acidification was blocked by a protein kinase inhibitor (PKI), implicating protein kinase A in the acidification. As the P2Y~12~ receptor is coupled to the inhibitory G~i~ protein, P2Y~12~ receptor antagonists will produce similar effects (Supplementary Figure [2](#SM2){ref-type="supplementary-material"}). Although ticagrelor can also inhibit the equilibrative nucleoside transporter 1 to raise extracellular adenosine ([@B29]; [@B2]; [@B3]), it is unlikely adenosine contributes much to the response in this study as plasma levels of ticagrelor in our treated mice were 0.87 ± 0.07 μM, while plasma levels of adenosine reached half -maximal concentrations with ∼30 μM ticagrelor ([@B29]). In addition, AR-C66931 does not act on ENT1 ([@B2]), and thus the ability of AR-C66931 to acidify lysosomes *in vitro* indicates P2Y~12~ antagonism is sufficient to lower lysosomal pH in these cells. Together, this implicates the P2Y~12~ receptor in mediating the effects of ticagrelor observed in this study.

Mechanisms for Reduced Autofluorescence
---------------------------------------

Ticagrelor may reduce autofluorescence from RPE cells through multiple pathways. For example, the lysosomal pH in RPE cells from ABCA4^-/-^ mice is alkalinized above age-matched controls ([@B25]) and lowering lysosomal pH with ticagrelor would enhance the activity of pH sensitive degradative lysosomal enzymes. Data above using Magic Red indicate cathepsin B activity in RPE cells is decreased by moderate elevations in lysosomal pH; this parallels the rise in cathepsin D activity following lysosomal acidification in RPE cells found previously ([@B16]). Acidifying lysosomal pH in RPE cells also enhanced the turnover of opsin derived from phagocytosed POSs, suggesting pH manipulation can enhance turnover of phagocytosed waste ([@B4]).

In addition to modulating the activity of lysosomal enzymes, decreased autofluorescence in RPE cells may reflect an enhanced exocytosis of waste material. The *bis*-retinoid A2E is present in high levels in the RPE cells of ABCA4^-/-^ mice ([@B27]). Although the endogenous breakdown of A2E is difficult ([@B45]), A2E shows a peak autofluorescence emission at 570 nm when excited at 380 nm ([@B37]), and the decrease in this emission in mice receiving ticagrelor suggests the A2E may be exocytosed. The TRPML1 channel contributes to the exocytosis of lysosomal waste; TRPML1 activity is pH dependent ([@B36]; [@B23]), and recent studies suggest the TRPML1 channel is particularly active in RPE cells ([@B14]). It is possible that enhanced exocytosis may contribute to the reduced autofluorescence in ABCA4^-/-^ mice receiving ticagrelor, although further experiments are needed to confirm this.

Remaining Issues
----------------

Several additional issues remain unresolved in this study. For example, it is not clear why elderly ABCA4^-/-^ mice required an extended treatment with ticagrelor before lysosomal pH was reduced, while there was no detectable trend between treatment length and the lysosomal acidification in mice receiving ticagrelor in their drinking water, especially as plasma concentrations of ticagrelor did not increase with prolonged dosage. Furthermore, it is unclear why the decline in RPE autofluorescence was limited to the inferior/nasal regions of the whole mounts. Regional differences in photoreceptor death occur with light damage models, with degree of light and differential levels of rhodopsin implicated ([@B31]); both of these parameters could influence the clearance of autofluorescence by ticagrelor. The mechanisms by which ticagrelor can decrease expression of CFH and ENT1 are also unclear; neither gene is linked to the CLEAR network directly regulated by lysosomal activity suggesting a more indirect connection ([@B32]). As discussed above, the relative effects of ticagrelor on lysosomal degradation versus exocytosis of autofluorescent waste are also relevant. Future work is needed to address these issues.

Relevance to Human Doses
------------------------

Given that ticagrelor is used in mainly elderly patients, the comparison of doses used here in mice with human dosage is relevant. Plasma levels in mice receiving 0.1% ticagrelor in food were 0.89 μM; this corresponds to 465 ng/mL and is close to levels in mice reported recently on 0.1% ticagrelor ([@B33]). In humans receiving the standard dose of 180 mg/day, plasma concentrations of ticagrelor ranged from a maximum of 770 ng/ml 2 h after dosing to a minimum of 227 ng/mL ([@B40], [@B38]). This suggests the levels of ticagrelor that lower lysosomal pH and decrease autofluorescence in mice are within the range found in patients. Whether treatments with ticagrelor can protect vision in ABCA4^-/-^ mice is currently being evaluated.

Portions of this work have previously been presented in abstract form ([@B26]).
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